Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Expert-led presentations & discussions on key abstracts in AML from ASCO and EHA 2023
Covering updates in newly diagnosed AML, FLT3, venetoclax-based regimens and IO/novel/early phase therapies
Session 1: Newly Diagnosed AML
Session 2: FLT3
Session 3: Venetoclax-based regimens
Session 4: IO/Novel/Early Phase
The Post-ASCO & EHA 2023 AML Highlights webinar has been supported by: